HIV Vaccine Research Study

STUDY BASICS

Are you 18 to 55 years old and living with HIV? You may be eligible for a research study to test an experimental HIV vaccine combined with an experimental adjuvant to see how the immune responses change among participants who do an antiretroviral analytical treatment interruption (ATI) compared to those who do not. Compensation is provided.

STUDY PURPOSE

The purpose of this study is to understand the following:

• Are the study products safe to use in people living with HIV, and can people take the study products without being too uncomfortable.
• How do people’s immune systems respond to the study products.
• How does the immune responses to the vaccine differ in people who are using HIV medicine and in people who stop taking HIV medicine in a carefully monitored analytical treatment interruption (ATI).
• Do people living with HIV make a special kind of immune response that is important for preventing HIV, and could that guide HIV vaccine development. 

COULD THIS STUDY BE RIGHT FOR YOU?

• Ages 18-55 years old
• HIV positive

WHAT PARTICIPANTS CAN EXPECT

• Screening involves a physical exam and asking about your health history. 
• This trial includes 2 doses of the experimental vaccine administered 12 weeks apart while participants remain on ART, followed by an Analytical Treatment Interruption (ATI) in one group and not ATI in the control group.  Participants will self-select the group in which they wish to participate due to the difference in the study visit schedules.  
• You will come to the clinic for scheduled visits for about a year and 2 months. The number of visits will depend on the group you are in. Most study visits will last about 1-2 hours.